MA51664A - Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-([5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino)-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide - Google Patents
Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-([5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino)-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amideInfo
- Publication number
- MA51664A MA51664A MA051664A MA51664A MA51664A MA 51664 A MA51664 A MA 51664A MA 051664 A MA051664 A MA 051664A MA 51664 A MA51664 A MA 51664A MA 51664 A MA51664 A MA 51664A
- Authority
- MA
- Morocco
- Prior art keywords
- cyclopropylmethyl
- isoxazole
- pyrimidin
- difluoro
- cyclopropyl
- Prior art date
Links
- 102100022716 Atypical chemokine receptor 3 Human genes 0.000 title 1
- 101000678890 Homo sapiens Atypical chemokine receptor 3 Proteins 0.000 title 1
- IIDSHAJKXPUYSL-FPOVZHCZSA-N N-[(3S,4S)-1-(cyclopropylmethyl)-3-[(1-pyrimidin-2-ylcyclopropyl)carbamoyl]piperidin-4-yl]-5-(2,4-difluorophenyl)-1,2-oxazole-3-carboxamide Chemical compound N1=C(N=CC=C1)C1(CC1)NC(=O)[C@H]1CN(CC[C@@H]1NC(=O)C1=NOC(=C1)C1=C(C=C(C=C1)F)F)CC1CC1 IIDSHAJKXPUYSL-FPOVZHCZSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2018051938 | 2018-01-26 | ||
| PCT/EP2019/051819 WO2019145460A1 (fr) | 2018-01-26 | 2019-01-25 | Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-{[5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino}-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA51664A true MA51664A (fr) | 2021-05-05 |
| MA51664B1 MA51664B1 (fr) | 2024-05-31 |
Family
ID=65139016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA51664A MA51664B1 (fr) | 2018-01-26 | 2019-01-25 | Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-([5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino)-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11339148B2 (fr) |
| EP (1) | EP3743422B1 (fr) |
| JP (1) | JP7076010B2 (fr) |
| KR (1) | KR102502046B1 (fr) |
| CN (1) | CN111683945B (fr) |
| AU (1) | AU2019212888B8 (fr) |
| BR (1) | BR112020015024A2 (fr) |
| CA (1) | CA3088478A1 (fr) |
| CL (1) | CL2020001928A1 (fr) |
| EA (1) | EA202091746A1 (fr) |
| ES (1) | ES2976567T3 (fr) |
| HR (1) | HRP20240552T1 (fr) |
| HU (1) | HUE066704T2 (fr) |
| IL (1) | IL276227B2 (fr) |
| MA (1) | MA51664B1 (fr) |
| MX (1) | MX392844B (fr) |
| MY (1) | MY206631A (fr) |
| PH (1) | PH12020551121A1 (fr) |
| PL (1) | PL3743422T3 (fr) |
| RS (1) | RS65594B1 (fr) |
| SG (1) | SG11202006943TA (fr) |
| TW (1) | TWI822724B (fr) |
| UA (1) | UA125327C2 (fr) |
| WO (1) | WO2019145460A1 (fr) |
| ZA (1) | ZA202005286B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA45782B1 (fr) | 2016-07-28 | 2021-12-31 | Idorsia Pharmaceuticals Ltd | Modulateurs du récepteur de cxcr7 pipéridine |
| JP7749552B2 (ja) * | 2019-10-31 | 2025-10-06 | イドルシア・ファーマシューティカルズ・リミテッド | Ｃｘｃｒ７アンタゴニストのｓ１ｐ１受容体調節剤との合剤 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1565436B1 (fr) | 2002-11-27 | 2012-04-25 | Incyte Corporation | Derives de la 3-aminopyrrolidine modulateurs des recepteurs de la chemoquine |
| TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| US7115646B2 (en) | 2003-10-08 | 2006-10-03 | Bristol Myers Squibb, Co. | Cyclic diamines and derivatives as factor Xa inhibitors |
| JP4058106B2 (ja) | 2005-02-18 | 2008-03-05 | アストラゼネカ アクチボラグ | 抗菌性のピペリジン誘導体 |
| WO2009011850A2 (fr) * | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Nouveaux composés thérapeutiques |
| JP6094578B2 (ja) | 2011-06-09 | 2017-03-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 代謝性障害の治療のためのｇｐｒ１１９モジュレーターとしての置換ピペリジン |
| WO2013084241A1 (fr) | 2011-12-09 | 2013-06-13 | Cadila Healthcare Limited | Composés inhibiteurs de rénine |
| AR091516A1 (es) | 2012-06-22 | 2015-02-11 | Actelion Pharmaceuticals Ltd | Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida |
| MX359651B (es) * | 2012-11-29 | 2018-10-05 | Chemocentryx Inc | Antagonistas de cxcr7. |
| MA38679B1 (fr) | 2013-05-30 | 2019-12-31 | Idorsia Pharmaceuticals Ltd | Modulateurs du récepteur de cxcr7 |
| CN105705489B (zh) | 2013-09-04 | 2019-04-26 | 百时美施贵宝公司 | 用作免疫调节剂的化合物 |
| HUE038169T2 (hu) | 2013-09-06 | 2018-09-28 | Aurigene Discovery Tech Ltd | 1,2,4-Oxadiazol származékok mint immunomodulátorok |
| WO2015044900A1 (fr) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Composés immunomodulateurs thérapeutiques |
| US20170253601A1 (en) * | 2014-09-10 | 2017-09-07 | Epizyme, Inc. | Substituted Pyrrolidine Compounds |
| CA2960280A1 (fr) | 2014-09-10 | 2016-03-17 | Epizyme, Inc. | Composes piperidines substitues |
| JP6582056B2 (ja) * | 2014-12-01 | 2019-09-25 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | Ｃｘｃｒ７受容体調節剤 |
| MA45782B1 (fr) * | 2016-07-28 | 2021-12-31 | Idorsia Pharmaceuticals Ltd | Modulateurs du récepteur de cxcr7 pipéridine |
-
2019
- 2019-01-25 WO PCT/EP2019/051819 patent/WO2019145460A1/fr not_active Ceased
- 2019-01-25 BR BR112020015024-0A patent/BR112020015024A2/pt unknown
- 2019-01-25 MA MA51664A patent/MA51664B1/fr unknown
- 2019-01-25 EP EP19701240.4A patent/EP3743422B1/fr active Active
- 2019-01-25 UA UAA202005451A patent/UA125327C2/uk unknown
- 2019-01-25 MY MYPI2020003778A patent/MY206631A/en unknown
- 2019-01-25 MX MX2020007881A patent/MX392844B/es unknown
- 2019-01-25 PL PL19701240.4T patent/PL3743422T3/pl unknown
- 2019-01-25 CN CN201980010015.7A patent/CN111683945B/zh active Active
- 2019-01-25 HU HUE19701240A patent/HUE066704T2/hu unknown
- 2019-01-25 AU AU2019212888A patent/AU2019212888B8/en active Active
- 2019-01-25 IL IL276227A patent/IL276227B2/en unknown
- 2019-01-25 SG SG11202006943TA patent/SG11202006943TA/en unknown
- 2019-01-25 RS RS20240646A patent/RS65594B1/sr unknown
- 2019-01-25 JP JP2020560586A patent/JP7076010B2/ja active Active
- 2019-01-25 ES ES19701240T patent/ES2976567T3/es active Active
- 2019-01-25 CA CA3088478A patent/CA3088478A1/fr active Pending
- 2019-01-25 TW TW108102825A patent/TWI822724B/zh active
- 2019-01-25 KR KR1020207024352A patent/KR102502046B1/ko active Active
- 2019-01-25 EA EA202091746A patent/EA202091746A1/ru unknown
- 2019-01-25 HR HRP20240552TT patent/HRP20240552T1/hr unknown
- 2019-01-25 US US16/964,885 patent/US11339148B2/en active Active
-
2020
- 2020-07-23 CL CL2020001928A patent/CL2020001928A1/es unknown
- 2020-07-24 PH PH12020551121A patent/PH12020551121A1/en unknown
- 2020-08-25 ZA ZA2020/05286A patent/ZA202005286B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3949382A4 (fr) | Architecture de capteur d'image | |
| EA201170251A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ | |
| EP3767709A4 (fr) | Composition d'électrode positive pour accumulateur au lithium-ion, électrode positive pour accumulateur au lithium-ion et accumulateur au lithium-ion | |
| EP2049110A4 (fr) | Diazépans pontés antagonistes du récepteur de l'oréxine | |
| MA28358A1 (fr) | Inhibiteurs de l'integrase du vih | |
| EA201891267A1 (ru) | Фармацевтическая композиция, содержащая действенный ингибитор urat1 | |
| MA28519B1 (fr) | Inhibiteurs de l'integrase du vih | |
| EP3930852A4 (fr) | Protéines de liaison à l'antigène se liant à bcma | |
| EP1725102A4 (fr) | Inhibiteurs de l'integrase du vih | |
| MA51664A (fr) | Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-([5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino)-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide | |
| MX2021010133A (es) | Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifl uorometil)-n-(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carbox amida monohidratada. | |
| EP4168985A4 (fr) | Compression d'image multiplans | |
| EP1881825A4 (fr) | Inhibiteurs de l'intégrase du vih | |
| MA54713A (fr) | Forme posologique parentérale stable d'acétate de cétrorélix | |
| EP4031039A4 (fr) | Plaque d'ostéotomie de nivellement du plateau tibial avec décalage | |
| CY1109694T1 (el) | Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης | |
| EP3920962A4 (fr) | Purification d'analogues de glp-1 | |
| EP3445763A4 (fr) | Nouvelles formes de sel cristallin du 3-(1,2,4-triazolo[4,3-a]pyridin-3-yléthynyl)-4-méthyl-n-(4-((4-méthylpipérazin-1-yl)méthyl)-3-trifluorométhylphényl)benzamide pour une application médicale | |
| EA200702612A1 (ru) | Соединения бензимидазолкарбоксамида в качестве агонистов рецепторов 5-нт | |
| EP3902545A4 (fr) | Nouveaux sels d'agents de dégradation sélectifs du récepteur des oestrogènes | |
| JP2007523166A5 (fr) | ||
| EP3924324A4 (fr) | Cocristal d'acide l-pipécolique de cannabidiol | |
| ATE525360T1 (de) | Neuartige imidazolinylmethyl-aryl-sulfonamide | |
| EP3740204A4 (fr) | Formes à l'état solide de fasoracétam | |
| EP3880305A4 (fr) | Forme cristalline d'acide 3- ((l-valyl) amino)-1-propanesulfonique |